Pfizer Inc  (PFE) Trade Now »     Rate PFE  -  Discuss PFE  -  Add to Watch List        

Home

Analysis & Videos

Quotes

Bull or Bear

Discuss

PFE: Bull or Bear?

From:    SocialPicks  |  Blogsphere  |  All

SocialPicks Community

A 130 / 30 Global Pharma ETF Strategy PFE

73%

-9.21% in 33 days <> Investors who are bullish on the generic drug industry may consider implementing a 130 / 30 global pharma investing strategy through equal-weight (5% each) short positions for the six brand drug companies outlined below with 30% of their assets while investing 130% of assets in long positions among generic drug makers. The list of brand drug companies with significant patent expiration exposure over the next 2-3 years includes Pfizer (NYSE: PFE ), GlaxoSmithKline (NYSE: GSK ), Takeda Pharma (OTC: TKPHY.PK ), Sanofi-Aventis ( SNY ), AstraZeneca ( AZN ), and Merck ( MRK ). ... Continue reading »

Pfizer Inc PFE <> <> <>   <><><><>< /><><><><><><><><><><><><><><><><><><><><><><><><>< />< />< />< />< />< /><>< />...

62%		+4.23% in 529 days Pfizer (PFE)   Click Here for the Strategy Report on this major drug manufacturer company Stocks Covered: Pfizer (PFE)   Target Returns:  7.56% or 15.33% Annualized * Downside Protection: Up to 6.12% Duration: 180 Days Investor Level: Beginner to Advanced Risk Level: Moderate Relative Risk <> <>
Analysts'  Recommendation:	Buy

FDA, Clinical Trial Calendar Updates: Weight Loss, Diabetes, and More PFE

73%

+20.76% in 217 days (closed on 11/04/09) Below is a summary of updates to the BioMedReports.com database of 246 entries included in the FDA and Clinical Trial Calendars .   http://biomedreports.com/fda-calendar.html   <> The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA deadline dates. The entries are updated on a daily basis as new information becomes available with a total of 110 entries through 4/1/09. The FDA Calendar includes the following information: company name, ticker, decision d... Continue reading »

Pfizer PFE

51%

+33.21% in 255 days Pfizer has lost a lot of market share. It's dividend yield is almost 10%, and has a low pe. It is going to move up. Continue reading »

Big Pharma Goes Generic PFE

73%

-6.13% in 34 days (closed on 04/01/09) Big Pharma Goes Generic <> <> <> <> <> <> Sanofi-Aventis (SNY) is now the 11 th largest generic drug maker in the world following its successful acquisition of Czech generic drug company Zentiva. As $70B in brand drug patents are set to expire through 2012, big pharma companies are hedging their bets through generic drug divisions, including Pfizer (PFE) - Greenstone, Novartis (NVS) - Sandoz, and the recently announced Merck (MRK) BioVent... Continue reading »

From the Blogosphere

Bristol Seeks EU OK for Apixaban – Analyst Blog

38%

Bristol-Myers Squibb Co. (BMY) and Pfizer (PFE) recently announced that they intend to seek European approval for apixaban, a drug aimed at preventing and treating clots in blood vessels. The companies will submit the application for the purpose in the first half of 2010. The oral drug is being developed and commercialized by the two companies through an agreement entered into in 2007.   The partners intend to seek approval for the candidate for treating patients who have undergone orthopedic surgery. The application will be supported by data from ADVANCE-2 and ADVANCE-3, studies which evalu... Continue reading »

Options Update: Pfizer, Bristol-Meyers and Merck volatility low

Filed under: Pfizer (PFE), Bristol-Myers Squibb (BMY), Merck and Co (MRK), Options Pfizer (PFE) closed at $18.49. December and January option implied volatility is at 27, March is at 28, versus its 26-week average of 32, according to Track Data, suggesting decreasing price movement. Bristol-Myers (BMY) closed at $25.14. Overall option implied volatility of 25 is below its 26-month average of 28, according to Track Data, suggesting decreasing price movement. <>Merck (MRK) closed at $36.70. December option implied volatility is at 27, January is at 28, below its 26-week average of 31, according t... Continue reading »

DJIA Market Wrap 5 December

N/A

The 60-minute trend is negative according to the force index indicator. The MACD indicator is printing a number of consecutive negative divergences. Prices are moving laterally within a trading range. The 10500 level has been tested already several times. Almost all stocks are moving above their short, medium and long term moving averages indicating how well the trend developed. DD, MCD, TRV printed a new 20-day low. Several stocks printed new 20-day highs; they are BA, CSCO, GE, INTC, JNJ, T, VZ. INTC and JNJ printed 5 consecutive up closes. In the Figure you can see a summary of the tren... Continue reading »

DJIA Market Wrap 5 December

The 60-minute trend is negative according to the force index indicator. The MACD indicator is printing a number of consecutive negative divergences. Prices are moving laterally within a trading range. The 10500 level has been tested already several times. Almost all stocks are moving above their short, medium and long term moving averages indicating how well the trend developed. DD, MCD, TRV printed a new 20-day low. Several stocks printed new 20-day highs; they are BA, CSCO, GE, INTC, JNJ, T, VZ. INTC and JNJ printed 5 consecutive up closes. In the Figure you can see a summary of the tren... Continue reading »

Bayer Advances on Alzheimer’s Plan – Analyst Blog

38%

Alzheimer’s disease (AD) is a devastating neuro-degenerative disease that affects people over the age of 60. The onset of the disease is often so gradual and the early signs are so mild that they are often mistaken as common traits of ageing.  Early detection of the disease is significant as many of the available treatment options are most effective in the early stages. However, there is no such detection test available currently although some are under trial.  The situation may change completely if Bayer (BAYRY) accomplishes its objective. The company recently decided to go ahead with th< />< />< />< />< />< />< />< />< />< /><><><><><><>< /><>< /><>< /><>< /><>< /><>< /><><>< /><>< /><>< />< />... Continue reading »

... more »  

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.